Recombinant Canine VEGF Protein

• Reactivity: Ca
• Applications: Bioactivity

Recombinant Canine VEGF Protein Summary

• Details of Functionality: Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED₅₀ for this effect is 1.5-7.5 ng/mL.
• Source: E. coli-derived canine VEGF protein
  Pro28-Arg190
• Accession #: AAD29682
• N-terminal Sequence: Pro28
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: VEGFA
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 19 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Canine VEGF Protein

• MVCD1
• VAS
• vascular endothelial growth factor A
• Vascular permeability factor
• Vasculotropin
• VEGF
• VEGFA
• VEGF-A
• VEGFMGC70609
• VPF
• VPFvascular endothelial growth factor

Background

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues. In human, at least eight alternately spliced isoforms of VEGF ranging from 206 amino acids (aa) to 121 aa in length are known. Three isoforms, VEGF₁₈₈, VEGF₁₈₂, and VEGF₁₆₄, have been identified in canine. Canine VEGF₁₆₄ shares 91%, 90%, and 98% aa sequence identity with the rat, mouse, and feline homologs, respectively. Two type I transmembrane receptor tyrosine kinases, VEGF R1 and VEGF R2, that bind VEGF with high affinity, have been identified. Neuropilin-1, a receptor for semaphorin, also binds VEGF and acts as a co-receptor to enhance the affinity between VEGF and VEGF R2. Neuropilin-1 alone can also mediate VEGF-induced endothelial cell migration. VEGF regulates cell proliferation, migration, and survival of endothelial cells. These functions are partially mediated through the induction of nitric oxide, prostacyclin, and metalloproteinases. Together with angiopoietins or other vascular-specific growth factors, VEGF plays a separate but complementary role in angiogenesis and vasculogenesis (1 - 7).

1. JingJing, L. et al. (2000) Mol. Cell Biochem. 214:23.
2. Scheidegger, P. et al. (1999) Biol. Chem. 380:1449.
3. Thurston, G. (2002) J. Anat. 200:575.
4. Zachary, I. and Gliki, G. (2001) Cardiovasc. Res. 49:568.
5. Chevalier, S. (2002) Mol. Cell Endocrinol.189:169.
6. Robinson, C.J. and Stringer, S.E. (2001) J. Cell. Sci. 114:853.
7. Wang, L. et al. (2003) J. Biol. Chem. 278:48848.

Publications for VEGF (1603-CV)(5)

Publications using 1603-CV

• LM Muellerlei, B Buxbaum, B Nell, DA Fux In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor Res. Vet. Sci., 2019-03-22;124(0):233-238. 2019-03-22 [PMID: 30933891] (ELISA, Western Blot, Canine)
• Ozelo M, Vidal B, Brown C, Notley C, Hegadorn C, Webster S, Harpell L, Ahlin J, Winterborn A, Handforth J, Arruda V, Hough C, Lillicrap D Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood, 2014-05-14;123(26):4045-53. 2014-05-14 [PMID: 24829206] (Bioassay, Canine)
• Kamstock D, Elmslie R, Thamm D Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol. Immunother., 2007-02-14;56(8):1299-309. 2007-02-14 [PMID: 17502972] (ELISA (Capture), Canine)
• Rebuzzi L, Willmann M, Sonneck K Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet. Immunol. Immunopathol., 2006-11-17;115(3):320-33. 2006-11-17 [PMID: 17196258] (Bioassay, Canine)
• Lin TY, London CA A functional comparison of canine and murine bone marrow derived cultured mast cells. Vet. Immunol. Immunopathol., 2006-10-06;114(3):320-34. 2006-10-06 [PMID: 17027994] (ELISA (Standard))

FAQs for VEGF (1603-CV). (Showing 1 - 1 of 1 FAQs).

1. Why is the molecular weight of VEGF different from the similar antibody, for some companies the the molecular weight is 40KD)?
   • I can't comment on another company's antibody because I don't have any information about their products. I can tell you that VEGF is expressed in a variety of isoforms and is subject to various post-translational modifications that influence its apparent molecular weight in an SDS-PAGE gel compared to the theoretical molecular weight.

Bioinformatics

• Gene Symbol: VEGFA
• Uniprot:
  • AAD29682()